/MAZE
MAZE Stock - Maze Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$41.71+2.68%
+$1.09 (+2.68%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+25.3%upside
Target: $52.26
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MAZE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$41.29 – $42.13
TARGET (TP)$52.25
STOP LOSS$38.37
RISK/REWARD1:3.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta4.58
52W High$43.29
52W Low$6.71
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $167.50M | N/A | N/A |
| Gross Profit | $167.50M | N/A | N/A |
| Gross Margin | 100.0% | N/A | N/A |
| Operating Income | $57.59M | $-98,551,000 | $-111,026,000 |
| Net Income | $52.23M | $-100,415,000 | $-114,940,000 |
| Net Margin | 31.2% | N/A | N/A |
| EPS | $0.08 | $-2.29 | $-2.63 |
Company Overview
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$34
Average Target
↓ 18.5% Downside
Now
$17
Low
$34
Average
$55
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 4th 2025 | Wells Fargo | Initiation | Overweight | $55 |
| November 14th 2025 | Raymond James | Initiation | Outperform | - |
| September 2nd 2025 | BTIG Research | Initiation | Buy | $30 |
| July 23rd 2025 | H.C. Wainwright | Initiation | Buy | $34 |
| July 8th 2025 | Wedbush | Initiation | Outperform | $17 |
Earnings History & Surprises
MAZEBeat Rate
50%
Last 4 quarters
Avg Surprise
-1052.3%
EPS vs Estimate
Beats / Misses
2/2
Last 12 quarters
Latest EPS
$-0.66
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q1 25
-4171.1%
$-18.32vs$0.45
Q2 25
-51.3%
$-1.15vs$-0.76
Q3 25
+2.5%
$-0.77vs$-0.79
Q4 25
+10.8%
$-0.66vs$-0.74
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.70 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.74 | $-0.66 | +10.8% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.79 | $-0.77 | +2.5% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.76 | $-1.15 | -51.3% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $0.45 | $-18.32 | -4171.1% | ✗ MISS |
Q3 2024 | Sep 30, 2024 | — | $-0.57 | — | — |
Q2 2024 | Jun 30, 2024 | — | $3.18 | — | — |
Q1 2024 | Mar 31, 2024 | — | $-0.74 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.61 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.57 | — | — |
Latest News
Wells Fargo Initiates Coverage On Maze Therapeutics with Overweight Rating, Announces Price Target of $55
📈 PositiveBenzinga•Dec 4, 2025, 01:39 PM
Maze Therapeutics shares are trading higher after HC Wainwright & Co. maintained a Buy rating on the stock and raised the price target from $50 to $60.
📈 PositiveBenzinga•Dec 3, 2025, 08:38 PM
HC Wainwright & Co. Maintains Buy on Maze Therapeutics, Raises Price Target to $60
📈 PositiveBenzinga•Dec 3, 2025, 07:18 PM
Wedbush Maintains Outperform on Maze Therapeutics, Raises Price Target to $36
📈 PositiveBenzinga•Nov 7, 2025, 03:06 PM
Maze Therapeutics Q3 EPS $(0.66) Beats $(0.71) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 10:02 PM
Maze Therapeutics To Present Data From Phase 1 Clinical Study Of MZE782 At American Society Of Nephrology
➖ NeutralBenzinga•Nov 6, 2025, 12:14 PM
Maze Therapeutics Expands Board Leadership With Appointment Of Hervé Hoppenot As Chairman Of Directors
📈 PositiveBenzinga•Oct 6, 2025, 11:13 AM
JP Morgan Maintains Overweight on Maze Therapeutics, Raises Price Target to $37
📈 PositiveBenzinga•Sep 29, 2025, 12:52 PM•Also:
HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $50 Price Target
📈 PositiveBenzinga•Sep 18, 2025, 10:41 AM
Guggenheim Maintains Buy on Maze Therapeutics, Raises Price Target to $34
📈 PositiveBenzinga•Sep 15, 2025, 12:40 PM
HC Wainwright & Co. Maintains Buy on Maze Therapeutics, Raises Price Target to $50
📈 PositiveBenzinga•Sep 12, 2025, 12:07 PM
BTIG Maintains Buy on Maze Therapeutics, Raises Price Target to $37
📈 PositiveBenzinga•Sep 12, 2025, 11:02 AM
Maze Therapeutics climbs after early-stage trial data for rare disease drug
📈 PositiveSeeking Alpha•Sep 11, 2025, 01:03 PM
Maze Therapeutics shares are trading higher after the company reported clinical results from its Phase 1 healthy volunteer study of MZE782. The company secured $150 million an an oversubscribed private placement.
📈 PositiveBenzinga•Sep 11, 2025, 12:55 PM
Maze Therapeutics rises on $150M equity offering
📈 PositiveSeeking Alpha•Sep 11, 2025, 11:45 AM
Maze Therapeutics Secures $150M In Oversubscribed Private Placement
📈 PositiveBenzinga•Sep 11, 2025, 11:37 AM
Maze Therapeutics Reports Clinical Results From Phase 1 Healthy Volunteer Study Of MZE782, Oral Small Molecule Targeting Solute Transporter, SLC6A19
➖ NeutralBenzinga•Sep 11, 2025, 11:33 AM
BTIG Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $30
📈 PositiveBenzinga•Sep 2, 2025, 12:12 PM
Maze Therapeutics Appoints Misbah Tahir CFO, Effective Immediately
📈 PositiveBenzinga•Sep 2, 2025, 11:05 AM
Frequently Asked Questions about MAZE
What is MAZE's current stock price?
Maze Therapeutics, Inc. (MAZE) is currently trading at $41.71 per share. The stock has moved +2.68% today.
What is the analyst price target for MAZE?
The average analyst price target for MAZE is $52.25, based on 1 analyst.
What sector is Maze Therapeutics, Inc. in?
Maze Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MAZE's market cap?
Maze Therapeutics, Inc. has a market capitalization of $2.01 billion, making it a mid-cap company.
Does MAZE pay dividends?
No, Maze Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARDX
Ardelyx, Inc.
$5.68
Mkt Cap: $1.4B
BCRX
BioCryst Pharmaceuticals, Inc.
$7.41
Mkt Cap: $1.6B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
SION
Sionna Therapeutics, Inc.
$42.37
Mkt Cap: $1.9B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
TRVI
Trevi Therapeutics, Inc.
$13.01
Mkt Cap: $1.7B
WVE
Wave Life Sciences Ltd.
$15.98
Mkt Cap: $2.6B
ZYME
Zymeworks Inc.
$27.23
Mkt Cap: $2.0B
Explore stocks similar to MAZE for comparison